Adlai Nortye Ltd. Sponsored ADR

ANL Healthcare Biotechnology

Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023. Dividend growth for five consecutive years.

11.07 1.02 −8.44%
Market cap
$710.1M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−22.05
Beneish M
n/a
Dividend safety
n/a
Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Altman Z-Score
— — (3.97) — (22.05)
Altman Z″-Score (non-manufacturers)
(0.91) — (9.17) — (53.99)
P/FCF ratio
0.00 — 0.00 — 0.00
P/Operating CF
0.00 — 0.00 — 0.00
P/B ratio
0.00 — 0.00 — 0.00
EV/Sales
0.00 — 0.00 — 0.00
EV/EBITDA
0.00 — 0.00 — 0.00
EV/FCF
0.00 — 0.00 — (0.01)
Current Ratio
7.12 0.21 2.04 1.41 0.65
Net Debt/EBITDA
13.57 0.88 0.95 0.66 (0.05)
Debt/Equity
(0.07) (0.02) 0.41 1.05 (3.09)
ROE
0.00% 26.21% 123.26% (103.19%) (414.01%)
ROA
0.00% (57.56%) (107.73%) (51.49%) (67.22%)
ROIC
0.00% 0.00% (615.01%) 0.00% 0.00%
Return on Tangible Assets
(51.20%) 24.23% (201.65%) (253.68%) 262.84%
Average Days of Receivables
0.00 — 0.00 — 0.00
Free Cash Flow Yield
0.00% — 0.00% — 0.00%
Free Cash Flow per Share
(0.49) (5.24) (3.94) (1.63) (1.05)
Book value per Share
(21.87) (28.45) 5.19 0.80 (0.26)
Free Cash Flow
(4.15) (44.47) (56.85) (51.96) (33.64)
EV/EBIT
0.00 — 0.00 — 0.00
Other line items

Show all line items

Columns are period end dates